Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease. (3rd October 2019)

• Record Type: Journal Article
• Authors: Mugisho, Odunayo O.; Rupenthal, Ilva D.; Paquet-Durand, Francois; Acosta, Monica L.; Green, Colin R.
• Is Part Of: Expert opinion on therapeutic targets. Volume 23:Number 10(2019:Oct.)
• Page Start: 855
• Page End: 863
• Publication Date: 2019-10-03
• Subjects: Inflammasome -- ocular disease -- chronic disease -- connexin hemichannel -- connexin43 -- NLRP3 activation -- inflammatory cytokine release; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2019.1673368
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Chronic inflammatory diseases, including retinal diseases that are a major cause of vision loss, are associated with activation of the nucleotide-binding domain and leucine-rich repeat containing (NLR) protein-3 (NLRP3) inflammasome pathway. In chronic disease, the inflammasome becomes self-perpetuating, indicating a common pathway in such diseases irrespective of underlying etiology, and implying a shared solution is feasible. Connexin43 hemichannels correlate directly with NLRP3 inflammasome complex assembly (shown here in models of retinal disease). Connexin43 hemichannel-mediated ATP release is proposed to be the principal activator signal for inflammasome complex assembly in primary signal-sensitized cells. Connexin hemichannel block on its own is sufficient to inhibit the inflammasome pathway. Areas covered : We introduce chronic retinal disease, discuss available preclinical models and examine findings from these models regarding the targeting of connexin43 hemichannels and its effects on the inflammasome. Expert opinion : In over 25 animal disease models, connexin hemichannel regulation has shown therapeutic benefit, and one oral connexin hemichannel blocker, tonabersat (Xiflam), is Phase II ready with safety evidence in over 1000 patients. Regulating the connexin hemichannel provides a means to move quickly into clinical trials designed to ameliorate the progression of devastating chronic diseases of the eye, but also elsewhere in the body.